14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:FPRX
Delisted

Five Prime Therapeutics Stock Price (Quote)

$38.00
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.00 $38.00 Friday, 27th May 2022 FPRX stock ended at $38.00. During the day the stock fluctuated 0% from a day low at $38.00 to a day high of $38.00.
90 days $38.00 $38.00
52 weeks $38.00 $38.00

Historical Five Prime Therapeutics prices

Date Open High Low Close Volume
Feb 29, 2016 $32.36 $33.05 $32.00 $32.57 673 300
Feb 26, 2016 $32.63 $33.76 $32.35 $32.58 385 300
Feb 25, 2016 $32.90 $33.32 $31.47 $32.65 368 800
Feb 24, 2016 $32.24 $33.20 $31.09 $32.81 293 600
Feb 23, 2016 $33.77 $34.21 $32.32 $32.51 432 600
Feb 22, 2016 $33.55 $34.71 $33.44 $33.72 305 500
Feb 19, 2016 $31.74 $33.70 $31.14 $33.58 378 300
Feb 18, 2016 $32.38 $33.00 $31.54 $31.75 600 000
Feb 17, 2016 $31.45 $33.00 $30.87 $32.77 429 700
Feb 16, 2016 $29.65 $31.59 $29.17 $31.39 496 400
Feb 12, 2016 $29.44 $29.64 $28.04 $29.35 334 800
Feb 11, 2016 $28.59 $29.48 $28.01 $29.04 339 300
Feb 10, 2016 $29.20 $30.50 $28.83 $29.22 598 000
Feb 09, 2016 $29.05 $30.96 $28.30 $29.04 526 000
Feb 08, 2016 $31.06 $31.49 $28.85 $29.16 530 500
Feb 05, 2016 $33.10 $33.14 $31.30 $31.54 376 200
Feb 04, 2016 $34.10 $35.63 $32.31 $33.26 598 300
Feb 03, 2016 $35.37 $35.58 $33.27 $34.42 415 800
Feb 02, 2016 $35.49 $35.49 $34.07 $35.16 342 900
Feb 01, 2016 $35.77 $36.89 $34.35 $35.53 503 900
Jan 29, 2016 $34.66 $35.95 $33.96 $35.95 464 200
Jan 28, 2016 $35.21 $35.84 $33.52 $34.75 426 200
Jan 27, 2016 $36.60 $36.88 $34.12 $35.00 653 900
Jan 26, 2016 $36.23 $38.18 $35.91 $36.80 480 400
Jan 25, 2016 $35.85 $37.17 $35.75 $36.34 450 400
Click to get the best stock tips daily for free!

About Five Prime Therapeutics

Five Prime Therapeutics Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II... FPRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT